512 related articles for article (PubMed ID: 26404016)
1. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.
Sterzing F; Kratochwil C; Fiedler H; Katayama S; Habl G; Kopka K; Afshar-Oromieh A; Debus J; Haberkorn U; Giesel FL
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):34-41. PubMed ID: 26404016
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.
Eiber M; Maurer T; Souvatzoglou M; Beer AJ; Ruffani A; Haller B; Graner FP; Kübler H; Haberkorn U; Eisenhut M; Wester HJ; Gschwend JE; Schwaiger M
J Nucl Med; 2015 May; 56(5):668-74. PubMed ID: 25791990
[TBL] [Abstract][Full Text] [Related]
3. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer.
Giesel FL; Fiedler H; Stefanova M; Sterzing F; Rius M; Kopka K; Moltz JH; Afshar-Oromieh A; Choyke PL; Haberkorn U; Kratochwil C
Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1794-800. PubMed ID: 26162799
[TBL] [Abstract][Full Text] [Related]
4. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.
Budäus L; Leyh-Bannurah SR; Salomon G; Michl U; Heinzer H; Huland H; Graefen M; Steuber T; Rosenbaum C
Eur Urol; 2016 Mar; 69(3):393-6. PubMed ID: 26116958
[TBL] [Abstract][Full Text] [Related]
5.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
6. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
7.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
8. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
9. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
[TBL] [Abstract][Full Text] [Related]
10. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
11. Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients.
Onal C; Torun N; Akyol F; Guler OC; Hurmuz P; Yildirim BA; Cağlar M; Reyhan M; Ozyigit G
Clin Nucl Med; 2019 Sep; 44(9):e510-e516. PubMed ID: 31283600
[TBL] [Abstract][Full Text] [Related]
12. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
13. Detection Rate and Localization of Prostate Cancer Recurrence Using
Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
[TBL] [Abstract][Full Text] [Related]
14. Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after
Schiller K; Sauter K; Dewes S; Eiber M; Maurer T; Gschwend J; Combs SE; Habl G
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1656-1662. PubMed ID: 28646463
[TBL] [Abstract][Full Text] [Related]
15. Retrospective correlation of
Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.
Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C
Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842
[TBL] [Abstract][Full Text] [Related]
17. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
Minamimoto R; Hancock S; Schneider B; Chin FT; Jamali M; Loening A; Vasanawala S; Gambhir SS; Iagaru A
J Nucl Med; 2016 Apr; 57(4):557-62. PubMed ID: 26659347
[TBL] [Abstract][Full Text] [Related]
18.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
19. The impact of [
Frenzel T; Tienken M; Abel M; Berliner C; Klutmann S; Beyersdorff D; Schwarz R; Krüll A; Bannas P
Strahlenther Onkol; 2018 Jul; 194(7):646-654. PubMed ID: 29572670
[TBL] [Abstract][Full Text] [Related]
20. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
